Menu Search
Equities

AtriCure Inc

ATRC:NMQ

AtriCure Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)35.68
  • Today's Change-0.35 / -0.97%
  • Shares traded1.44k
  • 1 Year change-14.44%
  • Beta1.4016
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AtriCure Inc grew revenues 20.84% from 330.38m to 399.25m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -46.47m to -30.44m.
Gross margin74.79%
Net profit margin-8.70%
Operating margin-7.94%
Return on assets-6.40%
Return on equity-8.39%
Return on investment-7.35%
More ▼

Cash flow in USDView more

In 2023, AtriCure Inc increased its cash reserves by 45.11%, or 26.21m. Cash Flow from Investing totalled 21.82m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 4.48m in cash from operations while cash used for financing totalled 32.00k.
Cash flow per share-0.4452
Price/Cash flow per share--
Book value per share9.54
Tangible book value per share3.53
More ▼

Balance sheet in USDView more

AtriCure Inc has a Debt to Total Capital ratio of 11.94%, a higher figure than the previous year's 10.91%.
Current ratio3.62
Quick ratio2.59
Total debt/total equity0.1355
Total debt/total capital0.1194
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.